Customizing inhaled therapy to meet the needs of COPD patients

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 83-93

  Fromer, Leonard ^a   Goodwin, Elizabeth ^b   Walsh, John ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

COPD; Inhaler therapy; Patient centered medical home model; Peak inspiratory flow

Indexed keywords

ARFORMOTEROL; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BROVANA INHALATION SOLUTION; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; DUONEB INHALATION SOLUTION; FLOVEN HFA INHALATION AEROSOL; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEVALBUTEROL; PERFOROMIST INHALATION SOLUTION; QVAR INHALATION AEROSOL; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VANCERIL INHALATION AEROSOL; BRONCHODILATING AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRY POWDER; HAND STRENGTH; HEALTH CARE NEED; HUMAN; INDIVIDUALIZATION; LIFESTYLE; LUNG FUNCTION; MEDICAL DECISION MAKING; METERED DOSE INHALER; NEBULIZER; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; POWDER INHALER; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; HEALTH SERVICE; HOME CARE; PEAK EXPIRATORY FLOW; UNITED STATES;

BRONCHODILATOR AGENTS; HEALTH SERVICES NEEDS AND DEMAND; HOME CARE SERVICES; HUMANS; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; PATIENT-CENTERED CARE; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 77950353163     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2125     Document Type: Review

References (81)

1. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-1504.
3. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555.
4. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-1276.
5. National Institutes of Health. National Heart Lung and Blood Institute. Morbidity and mortality: 2002 chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: NHLBI. 2002.
6. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf. 2004;27(10):689-715.
7. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290(17):2301-2312.
8. US Department of Health and Human Services. National Heart Lung and Blood Insitute. National Institutes of Health. 2007. http://www.nhlbi.nih.gov. Accessed September 28, 2009.
9. Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.com. 2008;91. Accessed September 28, 2009.
10. Filuk R. Delivery system selection: Clinical considerations. American Health and Drug Benefits. 2008;1(8):13-17.
11. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36(2):213-218.
12. Rau JL. Practical problems with aerosol therapy in COPD. Respir Care. 2006;51(2):158-172.
13. Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78-83.
14. Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function associated with ageing. Eur Respir J. 1999;13(1):197-205.
15. Foster JA, Yawn BP, Maziar A, Jenkins T, Rennard SI, Casebeer L. Enhancing COPD management in primary care settings. MedGenMed. 2007;9(3):24.
16. Dolovich MA. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care. 2000;45(6):597-608.
17. Tashkin DP. Multiple dose regimens. Impact on compliance. Chest. 1995;107(5 suppl):176S-182S.
18. Dolovich MB, Ahrens RC, Hess DR, et al; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371.
19. Bauer A, McGlynn P, Bovet L, Mims P, Curry L, Hanrahan JP. The influence of breathing pattern during nebulization on the emitted dose of arformoterol. Abstract. Chest. 2007;132(4):616S.
20. Bauer A, McGlynn P, Bovet L, Mims P, Curry L, Hanrahan JP. The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir Care. 2009;54(11):1488-1492.
21. Bauer A, McGlynn P, Bovet L, Mims P, Hanrahan JP. Aerosol properties of arformoterol inhalation solution in five nebulizer/compressor systems. Abstract. American Association for Respiratory Care Progam 2007, 113.
22. Thorsson L, Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide. Respir Med. 2005;99(7):836-849.
23. Dolovich MB. Drug delivery systems for administration of inhaled therapies in patients with chronic obstructive pulmonary disease. American Health and Drug Benefits. 2008;1(8):4-12.
24. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5(26):1-149.
25. Freedman T. Medihaler therapy for bronchial asthma; a new type of aerosol therapy. Postgrad Med. 1956;20(6):667-673.
26. United Nations Environment Programme. Montreal protocol on substances that deplete the ozone layer: 1991 assessment: Report of the technology and economic assessment panel. 1991. Accessed.
27. Tobyn M, Staniforth JN, Morton D, Harmer Q, Newton ME. Active and intelligent inhaler device development. Int J Pharm. 2004;277(1-2):31-37.
28. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395-2401.
29. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50(10):1360-1374; discussion 1374-1375.
30. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16(3):249-254.
31. Melani AS, Pirrelli M, Sestini P et al; Associazione Italiana Pneumologi Oppedalieri Educational Group. GENEBU Project. Equipment and drugs used for home nebulizer therapy in Italy. Monaldi Arch Chest Dis. 2002;57(5-6):231-236.
32. Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med. 1994;150(5 pt 1):1256-1261.
33. Khassawneh BY, Al-Ali MK, Alzoubi KH, et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care. 2008;53(3):324-328.
34. McFadden ER Jr. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy Clin Immunol. 1995;96(2):278-283.
35. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46(10):712-716.
36. Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest. 1994;105(1):111-116.
37. Gray SL, Williams DM, Pulliam CC, Sirgo MA, Bishop AL, Donohue JF. Characteristics predicting incorrect metered-dose inhaler technique in older subjects. Arch Intern Med. 1996;156(9):984-988.
38. Allen SC, Ragab S. Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age. Postgrad Med J. 2002;78(915):37-39.
39. Allen SC, Prior A. What determines whether an elderly patient can use a metered dose inhaler correctly? Br J Dis Chest. 1986;80(1):45-49.
40. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med. 2003;97(2):181-187.
41. Palander A, Mattila T, Karhu M, Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers: Buventol Easyhaler, Inspiryl Turbuhaler® and Ventoline Diskus. Clin Drug Invest. 2000;20(1):25-33.
42. Sarinas PS, Robinson TE, Clark AR, Canfield J Jr, Chitkara RK, Fick RB Jr. Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases. Chest. 1998;114(4):988-992.
43. Newman SP, Pitcairn GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J. 2000;16(1):178-183.
44. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75(1):18-25.
45. Cegla UH. Pressure and inspiratory flow characteristics of dry powder inhalers. Respir Med. 2004;98(suppl A):S22-S28.
46. van der Palen J. Peak inspiratory flow through diskus and turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL). Respir Med. 2003;97(3):285-289.
47. Atkins PJ. Dry powder inhalers: an overview. Respir Care. 2005;50(10):1304-1312; discussion 1312.
48. Nsour WM, Alldred A, Corrado J, Chrystyn H. Measurement of peak inhalation rates with an in-check meter to identify an elderly patient's ability to use a turbuhaler. Respir Med. 2001;95(12):965-968.
49. Seeto L, Lim S. Asthma and COPD. Inhalation therapy-clarity or confusion? Aust Fam Physician. 2001;30(6):557-561.
50. Maggi L, Bruni R, Conte U. Influence of the moisture on the performance of a new dry powder inhaler. Int J Pharm. 1999;177(1):83-91.
51. Geller DE. Comparing clinical features of the nebulizer, metereddose inhaler, and dry powder inhaler. Respir Care. 2005;50(10):1313-1321.
52. Roberts GW, Rossi SOP. Compatibility of nebuliser solutions. Aust J Hosp Pharm. 1993;23:35-37.
53. Coates AL, MacNeish CF, Lands LC, Meisner D, Kelemen S, Vadas EB. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers. Chest. 1998;113(4):951-956.
54. Kendrick AH, Smith EC, Wilson RS. Selecting and using nebuliser equipment. Thorax. 1997;52(suppl 2):S92-S101.
55. Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med. 1998;11(2):113-125.
56. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax. 1994;49(8):762-770.
57. Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care. 2004;49(2):174-179.
58. Smith EC, Denyer J, Kendrick AH. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J. 1995;8(7):1214-1221.
59. Barry PW, O'Callaghan C. An in vitro analysis of the output of budesonide from different nebulizers. J Allergy Clin Immunol. 1999;104(6):1168-1173.
60. Ho SL, Kwong WT, O'Drowsky L, Coates AL. Evaluation of four breath-enhanced nebulizers for home use. J Aerosol Med. 2001;14(4):467-475.
61. Kellerman R. The patient centred medical home-a new model of practice in the USA. Aust Fam Physician. 2009;38(5):279.
62. Irwin RS, Richardson ND. Patient-focused care: using the right tools. Chest. 2006;130(1 suppl):73S-82S.
63. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Affairs. 2001;20(6):64-78.
64. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care. 2005;50(10):1346-1356; discussion 1357-1359.
65. Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA. 2004;291(19):2359-2366.
66. Bateman ED. Introduction. Eur Respir Rev. 2005;14(96):83.
67. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1:67-86.
68. Kim CS, Garcia L. Delivery characteristics of albuterol powder aerosol by Rotahaler. J Aerosol Med. 1993;6(3):199-211.
69. Vidgren M, Paronen P, Vidgren P, Vainio P, Nuutinen J. In vivo evaluation of the new multiple dose powder inhaler and the Rotahaler using the gamma scintigraphy. Acta Pharm Nord. 1990;2(1):3-10.
70. Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm. 1994;102(1-3):127-132.
71. Newman SP. Drug delivery to the lungs from dry powder inhalers. Curr Opin Pulm Med. 2003;9(suppl 1):S17-S20.
72. Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med. 1998;92(1):105-110.
73. Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36(suppl 1):21-31.
74. Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7(1):69-73.
75. Malton A, Sumby BS, Dandiker Y. A comparison of in vitro drug delivery from salbutamol Diskus and terbutaline Turbohaler inhalers. J Pharm Med. 1996;6:35-48.
76. Thorsson L, Kenyon C, Newman SP, Borgstrom L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm. 1998;168(1):119-127.
77. Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ Jr. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001:14(3):309-315.
78. Boehringer Ingelheim Pharmaceuticals, Inc. Spiriva® Handihaler® (tiotropium bromide inhalation powder) Academy of Managed Care Pharmacy (AMCP) Formulary Dossier. http://medicaidprovider.hhs.mt.gov/pdf/spirivadossier.pdf. Accessed January 10, 2010.
79. Brand P, Meyer T, Weuthen T, et al. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007;47(10):1335-1341.
80. Bauer A, McGlynn P, Bovet LL, Mims PL, Curry LA, Hanrahan JP. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution. Respir Care. 2009;54(10):1342-1347.
81. Wieshammer S, Dreyhaupt J. Keystones of successful aerosol therapy (Letter to the editor/reply). Respiration. 2009;78(3):357-358.